Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      FDA Expands Gardasil 9 Approval for HPV-Related Cancers

      June 15, 2020
      By Brielle Benyon
      Article

      On Friday, the FDA expanded the approval for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) types 16,18,31, 33, 45, 52, and 58, according to Merck, the manufacturer of the vaccine.

      On Friday, the FDA expanded the approval for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) types 16,18,31, 33, 45, 52, and 58, according to Merck, the manufacturer of the vaccine.

      According to the CDC, the majority (80%) of sexually active adults in the United States contract HPV within their lifetime. For most people, the virus clears up on its own, but for others, it can become cancerous — making vaccines like Gardasil 9 important.

      While both men and women can contract HPV-related oropharyngeal cancer, the disease affects men 5 times more than women. Oropharyngeal cancer — the most prevalent type of HPV-related cancer in the United States – can be caused by an HPV infection in the oropharynx, which includes the soft palate, side and back wall of the throat, tonsils, and back third of the tongue.

      “At Merck, working to help prevent certain HPV-related cancers has been a priority for more than two decades,” Alain Luxembourg, MD, director, clinical research, Merck Research Laboratories, said in a press release.

      Gardasil 9 is already approved to prevent HPV-related cervical, vulvar, vaginal, and anal cancers, as well as dysplastic lesions and genital warts in females between the ages of 9 and 45. It is also approved for males between the ages of 9 and 45 to prevent HPV-related anal cancer or dysplastic lesions and genital warts.

      Most common adverse events (AEs) in females (occurring in 10% or more of patients) were injection-site pain, swelling, erythema, and headache. For males, common AEs were injection-site pain, swelling, and erythema.

      “Today’s approval for the prevention of HPV-related oropharyngeal and other head and neck cancers represents an important step in Merck’s mission to help reduce the number of men and women affected by certain HPV-related cancers,” Luxembourg said.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Elizabeth Cullen
      Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection
      Related Content

      Line illustration of the male genitourinary tract

      Ga-68 Kit Approved for Pre-Taxane RLT Selection in mCRPC

      Bridget Hoyt
      June 24th 2025
      Article

      Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane chemotherapy.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Illustration of two medical workers holding up a magnifying glass to a cross-section of a bone

      Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment

      Bridget Hoyt
      June 21st 2025
      Article

      Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.


       Shawna Douglas On How Nurse Navigators Help Ease the Treatment Burden for Patients With Head and Neck Cancer

      Shawna Douglas On How Nurse Navigators Help Ease the Treatment Burden for Patients With Head and Neck Cancer

      Lindsay Fischer
      September 1st 2023
      Podcast

      Shawna Douglas, BSN, RN, discusses the role that nurse navigators play in caring for patients with head and neck cancer.


      Graphic that resembles a stamp of approval reading "FDA Approved"

      FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

      Bridget Hoyt
      June 12th 2025
      Article

      The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.


      Graphic of a clipboard that reads "FDA"

      Zanubrutinib Tablets Greenlit by FDA for All Approved Indications

      Bridget Hoyt
      June 12th 2025
      Article

      An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and Waldenström macroglobulinemia.

      Related Content

      Line illustration of the male genitourinary tract

      Ga-68 Kit Approved for Pre-Taxane RLT Selection in mCRPC

      Bridget Hoyt
      June 24th 2025
      Article

      Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane chemotherapy.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Illustration of two medical workers holding up a magnifying glass to a cross-section of a bone

      Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment

      Bridget Hoyt
      June 21st 2025
      Article

      Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.


       Shawna Douglas On How Nurse Navigators Help Ease the Treatment Burden for Patients With Head and Neck Cancer

      Shawna Douglas On How Nurse Navigators Help Ease the Treatment Burden for Patients With Head and Neck Cancer

      Lindsay Fischer
      September 1st 2023
      Podcast

      Shawna Douglas, BSN, RN, discusses the role that nurse navigators play in caring for patients with head and neck cancer.


      Graphic that resembles a stamp of approval reading "FDA Approved"

      FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

      Bridget Hoyt
      June 12th 2025
      Article

      The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.


      Graphic of a clipboard that reads "FDA"

      Zanubrutinib Tablets Greenlit by FDA for All Approved Indications

      Bridget Hoyt
      June 12th 2025
      Article

      An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and Waldenström macroglobulinemia.

      Latest Conference Coverage

      No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC

      Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.